Finkelstein Thompson LLP Announces Investigation Of Affymax, Inc.

WASHINGTON--(BUSINESS WIRE)--The law firm Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Affymax, Inc. (“Affymax” or “the Company”) (Nasdaq: AFFY). Finkelstein Thompson’s investigation relates to the recent announcement by Affymax and partner Takeda Pharmaceutical that they were voluntarily recalling all lots of Omontys, Affymax’s flagship anemia drug.

Affymax’s recall allegedly resulted from reports of severe allergic reactions in some kidney-disease patients, culminating in at least five deaths. On Sunday, February 24, 2013, the U.S. Food and Drug Administration alerted healthcare providers about the Omontys recall. The next day -- Monday, February 25, 2013 -- Affymax’s share price plummeted as much as 85% from the Friday’s close. The investigation focuses on whether Affymax violated state or federal laws in connection with its public statements regarding Omontys’s side effects and the subsequent recall of the drug.

If you are interested in discussing your rights as an Affymax shareholder, or have information relating to this investigation, please contact Finkelstein Thompson’s Washington, DC offices at (202)-337-8000 or by email at [e-mail].

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our website at www.finkelsteinthompson.com. Attorney advising. Prior results do not guarantee similar outcomes.